Dtsch Med Wochenschr 2011; 136(5): e1
DOI: 10.1055/s-0031-1272976
Erratum

© Georg Thieme Verlag KG Stuttgart · New York

Koronare Herzkrankheit – Was ist wichtig nach der Koronarintervention?

Coronary heart disease – what is of importance after coronary intervention?T. Rassaf1 , C. W. Hamm2
  • 1Klinik für Kardiologie, Pneumologie, Angiologie, Universitätsklinikum Düsseldorf
  • 2Abteilung für Kardiologie, Kerckhoff Klinik gGmbH, Herz und Thoraxzentrum
Further Information

Publication History

Publication Date:
31 January 2011 (online)

Also available at
    Permissions and Reprints

Correction to:

Koronare Herzkrankheit – Was ist wichtig nach der Koronarintervention?Dtsch Med Wochenschr 2011; 136(05): 190-193
DOI: 10.1055/s-0031-1272507

Im Beitrag "Koronare Herzkrankheit – Was ist wichtig nach der Koronarintervention? " muss die englische Zusammenfassung korrekt lauten:

In the European Union Ticagrelor has recently been approved, as another P2Y12-receptor antagonist in addition to clopidogrel and prasugrel, in the drug treatment after coronary intervention. Dual antithrombotic treatment must be given for 4 weeks after elective implantation of bare-metal stents, or for at least 6 months with acetylsalicylic acid (ASA) plus clopidogrel after implantation of a drug-eluting stent. After an acute coronary syndrome ASA and clopidogrel (or prasugrel or ticagrelor) must be given for 12 months. In patients requiring urgent oral anticoagulation essential triple-drug treatment should be given over as short a space of time as possible. Prasugrel and ticagrelor may, to protect against gastroduodenal bleeding, be given without restriction together with a proton-pump inhibitor. Preoperative coagulation management is essential for patients who have been on dual platelet-aggregation inhibitors, but premature withdrawal of this medication should be avoided.

      >